

# Maria Beatrice Musumeci

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9513984/publications.pdf>

Version: 2024-02-01

69  
papers

1,027  
citations

471477

17  
h-index

526264

27  
g-index

69  
all docs

69  
docs citations

69  
times ranked

1460  
citing authors

#	ARTICLE	IF	CITATIONS
1	Low Sensitivity of Bone Scintigraphy in Detecting Phe64Leu Mutation-Related Transthyretin Cardiac Amyloidosis. <i>JACC: Cardiovascular Imaging</i> , 2020, 13, 1314-1321.	5.3	82
2	Cardiopulmonary exercise test and sudden cardiac death risk in hypertrophic cardiomyopathy. <i>Heart</i> , 2016, 102, 602-609.	2.9	50
3	Eligibility for the Subcutaneous Implantable Cardioverter-Defibrillator in Patients With Hypertrophic Cardiomyopathy. <i>Journal of Cardiovascular Electrophysiology</i> , 2015, 26, 893-899.	1.7	45
4	Usefulness of Electrocardiographic Patterns at Presentation to Predict Long-term Risk of Cardiac Death in Patients With Hypertrophic Cardiomyopathy. <i>American Journal of Cardiology</i> , 2016, 118, 432-439.	1.6	45
5	Unmasking the prevalence of amyloid cardiomyopathy in the real world: results from Phase 2 of the AC-TIVE study, an Italian nationwide survey. <i>European Journal of Heart Failure</i> , 2022, 24, 1377-1386.	7.1	43
6	Incidence and determinants of high-sensitivity troponin and natriuretic peptides elevation at admission in hospitalized COVID-19 pneumonia patients. <i>Internal and Emergency Medicine</i> , 2020, 15, 1467-1476.	2.0	42
7	Heart Failure Progression in Hypertrophic Cardiomyopathy – Possible Insights From Cardiopulmonary Exercise Testing. <i>Circulation Journal</i> , 2016, 80, 2204-2211.	1.6	41
8	Calcium Channel Blockers and Hypertension. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2015, 20, 121-130.	2.0	40
9	Arterial thrombo-embolic events in cardiac amyloidosis: a look beyond atrial fibrillation. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2021, 28, 12-18.	3.0	38
10	Gender Differences in Takotsubo Syndrome. <i>Journal of the American College of Cardiology</i> , 2022, 79, 2085-2093.	2.8	33
11	Pulmonary hypertension and clinical correlates in hypertrophic cardiomyopathy. <i>International Journal of Cardiology</i> , 2017, 248, 326-332.	1.7	28
12	Incidence and risk factors for pacemaker implantation in light-chain and transthyretin cardiac amyloidosis. <i>European Journal of Heart Failure</i> , 2022, 24, 1227-1236.	7.1	28
13	Admission heart rate and in-hospital course of patients with Takotsubo syndrome. <i>International Journal of Cardiology</i> , 2018, 273, 15-21.	1.7	23
14	A national survey on prevalence of possible echocardiographic red flags of amyloid cardiomyopathy in consecutive patients undergoing routine echocardiography: study design and patients characterization – the first insight from the AC-TIVE Study. <i>European Journal of Preventive Cardiology</i> , 2022, 29, e173-e177.	1.8	21
15	Incidence, determinants and prognostic relevance of dyspnea at admission in patients with Takotsubo syndrome: results from the international multicenter GEIST registry. <i>Scientific Reports</i> , 2020, 10, 13603.	3.3	20
16	A Next-Generation Sequencing Approach to Identify Gene Mutations in Early- and Late-Onset Hypertrophic Cardiomyopathy Patients of an Italian Cohort. <i>International Journal of Molecular Sciences</i> , 2016, 17, 1239.	4.1	19
17	Nocturnal blood pressure patterns and cardiovascular outcomes in patients with masked hypertension. <i>Journal of Clinical Hypertension</i> , 2018, 20, 1238-1246.	2.0	19
18	Clinical and prognostic impact of chronotropic incompetence in patients with hypertrophic cardiomyopathy. <i>International Journal of Cardiology</i> , 2018, 271, 125-131.	1.7	19

#	ARTICLE	IF	CITATIONS
19	Clinical application of CMR in cardiomyopathies: evolving concepts and techniques. <i>Heart Failure Reviews</i> , 2023, 28, 77-95.	3.9	19
20	Tortuosity, Recurrent Segments, and Bridging of the Epicardial Coronary Arteries in Patients With the Takotsubo Syndrome. <i>American Journal of Cardiology</i> , 2017, 119, 243-248.	1.6	18
21	Prognostic Implications of Defibrillation Threshold Testing in Patients With Hypertrophic Cardiomyopathy. <i>Journal of Cardiovascular Electrophysiology</i> , 2017, 28, 103-108.	1.7	18
22	Current patterns of beta-blocker prescription in cardiac amyloidosis: an Italian nationwide survey. <i>ESC Heart Failure</i> , 2021, 8, 3369-3374.	3.1	18
23	Real-world versus trial patients with transthyretin amyloid cardiomyopathy. <i>European Journal of Heart Failure</i> , 2019, 21, 1479-1481.	7.1	17
24	Prognostic relevance of GRACE risk score in Takotsubo syndrome. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2020, 9, 721-728.	1.0	16
25	Long-Term Left Ventricular Remodeling of Patients With Hypertrophic Cardiomyopathy. <i>American Journal of Cardiology</i> , 2018, 122, 1924-1931.	1.6	15
26	Risk Stratification in Hypertrophic Cardiomyopathy. Insights from Genetic Analysis and Cardiopulmonary Exercise Testing. <i>Journal of Clinical Medicine</i> , 2020, 9, 1636.	2.4	15
27	Coronavirus disease 2019 in patients with cardiovascular disease: clinical features and implications on cardiac biomarkers assessment. <i>Journal of Cardiovascular Medicine</i> , 2021, 22, 832-839.	1.5	15
28	Sacubitril/Valsartan as a Therapeutic Tool Across the Range of Heart Failure Phenotypes and Ejection Fraction Spectrum. <i>Frontiers in Physiology</i> , 2021, 12, 652163.	2.8	14
29	Electrocardiographic evolution in patients with hypertrophic cardiomyopathy who develop a left ventricular apical aneurysm. <i>Journal of Electrocardiology</i> , 2015, 48, 818-825.	0.9	12
30	Long-Term Outcome of Acute Coronary Syndromes in Young Patients. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2017, 24, 77-84.	2.2	12
31	Myocardial Repolarization Dispersion and Late Gadolinium Enhancement in Patients With Hypertrophic Cardiomyopathy. <i>Circulation Journal</i> , 2014, 78, 1216-1223.	1.6	11
32	QT spatial dispersion and sudden cardiac death in hypertrophic cardiomyopathy: Time for reappraisal. <i>Journal of Cardiology</i> , 2017, 70, 310-315.	1.9	11
33	The neglected issue of cardiac amyloidosis in trials on heart failure with preserved ejection fraction in the elderly. <i>European Journal of Heart Failure</i> , 2020, 22, 1740-1741.	7.1	11
34	Left Ventricular Remodeling in Hypertrophic Cardiomyopathy: An Overview of Current Knowledge. <i>Journal of Clinical Medicine</i> , 2021, 10, 1547.	2.4	11
35	Happy Heart Syndrome. <i>JACC: Heart Failure</i> , 2022, 10, 459-466.	4.1	11
36	Safety and efficacy of anti-tachycardia pacing in patients with hypertrophic cardiomyopathy implanted with an ICD. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2019, 42, 610-616.	1.2	10

#	ARTICLE	IF	CITATIONS
37	Clinical characteristics of patients with takotsubo syndrome recurrence: An observational study with long-term follow-up. <i>International Journal of Cardiology</i> , 2021, 329, 23-27.	1.7	10
38	A systematic review on focal takotsubo syndrome: a not-so-small matter. <i>Heart Failure Reviews</i> , 2022, 27, 271-280.	3.9	9
39	Subcutaneous implantable cardioverter defibrillator in cardiomyopathies and channelopathies. <i>Journal of Cardiovascular Medicine</i> , 2018, 19, 633-642.	1.5	8
40	Therapeutic Approach to Hypertension Urgencies and Emergencies During Acute Coronary Syndrome. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2018, 25, 253-259.	2.2	8
41	Nerve ultrasonography findings as possible pitfall in differential diagnosis between hereditary transthyretin amyloidosis with polyneuropathy and chronic inflammatory demyelinating polyneuropathy. <i>Neurological Sciences</i> , 2020, 41, 3775-3778.	1.9	8
42	Novel Imaging and Genetic Risk Markers in Takotsubo Syndrome. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 703418.	2.4	8
43	Long-Term Tolerability and Efficacy of the Fixed Combination of Manidipine and Delapril in Patients with Essential Hypertension. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2003, 10, 81-86.	2.2	7
44	Attitudes and preferences for the clinical management of patients with hypertension and hypertension with chronic obstructive pulmonary disease in Italy: main results of a survey questionnaire. <i>Internal and Emergency Medicine</i> , 2015, 10, 943-954.	2.0	7
45	Distinguishing Hypertension From Hypertrophic Cardiomyopathy as a Cause of Left Ventricular Hypertrophy. <i>Journal of Clinical Hypertension</i> , 2015, 17, 239-241.	2.0	6
46	Effects of different statin types and dosages on systolic/diastolic blood pressure: Retrospective analysis of 24-hour ambulatory blood pressure database. <i>Journal of Clinical Hypertension</i> , 2018, 20, 967-975.	2.0	6
47	24-Hour ambulatory blood pressure levels and control in a large cohort of adult outpatients with different classes of obesity. <i>Journal of Human Hypertension</i> , 2019, 33, 298-307.	2.2	6
48	The natural history of hypertrophic cardiomyopathy. <i>European Heart Journal Supplements</i> , 2020, 22, L11-L14.	0.1	6
49	Spatial QT Dispersion Predicts Nonsustained Ventricular Tachycardia and Correlates with Confined Systodiastolic Dysfunction in Hypertrophic Cardiomyopathy. <i>Cardiology</i> , 2015, 131, 122-129.	1.4	5
50	Attitudes and preferences for the clinical management of hypertension and hypertension-related cerebrovascular disease in the general practice: results of the Italian hypertension and brain survey. <i>Clinical Hypertension</i> , 2017, 23, 10.	2.0	5
51	Prognostic implications of nonsustained ventricular tachycardia morphology in high-risk patients with hypertrophic cardiomyopathy. <i>Journal of Cardiovascular Electrophysiology</i> , 2020, 31, 2093-2098.	1.7	5
52	Yield of bone scintigraphy screening for transthyretin-related cardiac amyloidosis in different conditions: Methodological issues and clinical implications. <i>European Journal of Clinical Investigation</i> , 2021, 51, e13665.	3.4	5
53	Prevalence and prognostic role of nonsustained ventricular tachycardia in cardiac amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2022, 29, 211-212.	3.0	5
54	RyR2 Common Gene Variant G1886S and the Risk of Ventricular Arrhythmias in ICD Patients with Heart Failure. <i>Journal of Cardiovascular Electrophysiology</i> , 2015, 26, 656-661.	1.7	4

#	ARTICLE	IF	CITATIONS
55	Long-term management of Takotsubo syndrome: a not-so-benign condition. <i>Reviews in Cardiovascular Medicine</i> , 2021, 22, 597.	1.4	4
56	Insights from Cardiopulmonary Exercise Testing in Pediatric Patients with Hypertrophic Cardiomyopathy. <i>Biomolecules</i> , 2021, 11, 376.	4.0	3
57	TNNI3 and KCNQ1 co-inherited variants in a family with hypertrophic cardiomyopathy and long QT phenotypes: A case report. <i>Molecular Genetics and Metabolism Reports</i> , 2021, 27, 100743.	1.1	3
58	TP-interval predicts heart rate reduction after fingolimod administration in patients with multiple sclerosis. <i>International Journal of Cardiology</i> , 2016, 221, 881-885.	1.7	2
59	Autonomic cardiovascular control and cardiac arrhythmia in two pregnant women with hypertrophic cardiomyopathy: Insights from ICD monitoring. <i>Revista Portuguesa De Cardiologia</i> , 2018, 37, 351.e1-351.e4.	0.5	2
60	The Many Faces of Arterial Hypertension in Hypertrophic Cardiomyopathy and Its Phenocopies: Bystander, Consequence, Modifier. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2021, 28, 327-329.	2.2	2
61	Takotsubo syndrome: hyperthyroidism, pheochromocytoma, or both? A case report. <i>European Heart Journal - Case Reports</i> , 2021, 5, ytab270.	0.6	2
62	Transcatheter aortic valve replacement for aortic regurgitation after septal myectomy in patients with obstructive hypertrophic cardiomyopathy. <i>Cardiovascular Revascularization Medicine</i> , 2020, 28S, 225-226.	0.8	1
63	Oxidative Stress and Cardiovascular Disease. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2003, 10, 27-33.	2.2	0
64	Response to letter from Madias regarding our article "Admission heart rate and in-hospital course of patients with Takotsubo syndrome". <i>International Journal of Cardiology</i> , 2019, 274, 64.	1.7	0
65	A Plea for Smoking-Free Policies in COVID-19 Times: Cardiovascular Prevention as an Ally in Coronavirus Containment. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2021, 28, 325-326.	2.2	0
66	Reply to the letter "Takotsubo syndrome: Any more covariates of its recurrence?". <i>International Journal of Cardiology</i> , 2021, 333, 54.	1.7	0
67	MR-Proanp and VEGF As Markers of Response to MEL-DEX Treatment in Systemic AL Amyloidosis. <i>Blood</i> , 2012, 120, 4970-4970.	1.4	0
68	Unmasking the prevalence of cardiac amyloidosis in the real world: first insights from the phase 2 of active study, an Italian nationwide survey. <i>European Heart Journal Supplements</i> , 2021, 23, .	0.1	0
69	The Swiss cheese model in takotsubo syndrome. <i>European Heart Journal - Case Reports</i> , 2022, 6, .	0.6	0